Search Results

Alcresta Therapeutics, Inc. today announced the commercial availability of the next-generation RELiZORB® (iMMOBILIZED LIPASE) cartridge.

Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced 510(k) clearance of its next-generation RELiZORB® (iMMOBILIZED LIPASE) cartridge by the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA).

Alcresta Therapeutics, Inc. today announced the publication of a position paper in the May issue of the Journal of Cystic Fibrosis.

Alcresta Therapeutics, Inc., a leading commercial-stage company focused on developing and commercializing novel enzyme-based products, today announced that the U.S. Food and Drug Administration (FDA) has cleared expanded use of RELiZORB® to children ages 2 to <5 years.

Alcresta Therapeutics, Inc. today announced publication of preclinical data from the company’s development device ALC-078 in a porcine short bowel syndrome (SBS) model.

Alcresta Therapeutics, Inc. today announced a series of commercial milestone achievements.

Alcresta Therapeutics, Inc. announced the appointment of Chris Parrish as its Chief Operations Officer (COO) effective November 29, 2021.

Alcresta Therapeutics, Inc. today announced publication of preclinical data from the company’s development device, ALC-078, in a porcine short bowel syndrome (SBS) model.

Alcresta Therapeutics, Inc. today announced that the Centers for Medicare & Medicaid Services (CMS) has published a Local Coverage Determination (LCD) on enteral nutrition (LCD ID No. 38955) that confirms coverage for RELiZORB® (immobilized lipase).